Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 15/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25175304 | 0.78 | KIF11 (0.35) | KIF11CYP2D6 | |
| SCHEMBL9408984 | 0.76 | KIF11 (0.40) | KIF11CYP1A2CYP2D6KCNN4 | |
| SCHEMBL7396136 | 0.76 | KIF11 (0.35) | KIF11CYP1A2 | |
| SCHEMBL6363063 | 0.76 | KIF11 (0.36) | KIF11KCNN4 | |
| SCHEMBL18704761 | 0.76 | KIF11 (0.36) | KIF11CYP1A2CYP2D6 | |
| SCHEMBL8853209 | 0.72 | CYP2D6 (0.39) | KIF11CYP1A2CYP2D6 | |
| SCHEMBL21082668 | 0.72 | KIF11 (0.38) | KIF11CYP1A2CYP2D6KCNN4 | |
| SCHEMBL22467851 | 0.72 | KIF11 (0.42) | KIF11CYP1A2CYP2D6KCNN4 | |
| SCHEMBL358276 | 0.72 | KIF11 (0.46) | KIF11CYP1A2CYP2D6 | |
| SCHEMBL13956837 | 0.71 | KIF11 (0.36) | KIF11CYP1A2CYP2D6KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050266496-A1 | Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-12-01 | — | — | US | disclosed |
| US-20030144260-A1 | Heterocyclic compounds, method of developing new drug leads and combinatorial libraries used in such method | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-07-31 | — | — | US | disclosed |
| EP-0618221-A2 | Heterocyclic inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144260-A1 | Heterocyclic compounds, method of developing new drug leads and combinatorial libraries used in such method | AADAC, ABCG2, HDAC3 | KIF11 3317/4885CYP1A2 718/4885CYP2D6 409/4885 |
| US-20050266496-A1 | Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads | AADAC, ABCG2, RICTOR | KIF11 3214/4885CYP1A2 669/4885CYP2D6 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.